Loading…
Reported covered position: Chief Counsel US Senate HELP Committee, Employment sub-committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Helping Experts Accelerate Rare Treatments Act of 2021
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184 and S 4071
Helping Experts Accelerate Rare Treatments Act of 2021
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2026 · third_quarter · Q3
General issue awareness related to ultra-rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2026 · second_quarter · Q2
Source: Senate LDA
| USAGINASTALZHEIMER'S NETWORK |
| 10 |
| 2017–2019 |
| AKCEA THERAPEUTICS, INC. | 7 | 2019–2020 |
| THERABRON THERAPEUTICS, INC | 7 | 2015–2016 |
| FERRING PHARMACEUTICALS, INC. | 4 | 2019 |
| STARKEY HEARING TECHNOLOGIES | 4 | 2017 |
| BIOMARIN PHARMACEUTICAL INC. | 3 | 2016 |
| IMARA, INC. | 2 | 2017 |
| ALPHA-1 FOUNDATION | 1 | 2020 |
| BINGE EATING DISORDER ASSOCIATION | 1 | 2017 |
| NATIONAL EATING DISORDER ASSOCCIATION | 1 | 2017 |
Helping Experts Accelerate Rare Treatments Act of 2021
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184 and S 4071
Helping Experts Accelerate Rare Treatments Act of 2021
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Helping Experts Accelerate Rare Treatments Act of 2021
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184 and S 4071
Helping Experts Accelerate Rare Treatments Act of 2021
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Helping Experts Accelerate Rare Treatments Act of 2021
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071
Helping Experts Accelerate Rare Treatments Act of 2021
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR7567 The Access to Rare Indications Act HEART Act.
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
Helping Experts Accelerate Rare Treatments Act of 2022
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184 and S 4071
Helping Experts Accelerate Rare Treatments Act of 2022
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184 and S 4071
Helping Experts Accelerate Rare Treatments Act of 2022
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071
Helping Experts Accelerate Rare Treatments Act of 2022
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Helping Experts Accelerate Rare Treatments Act of 2022
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184 and S 4071
Helping Experts Accelerate Rare Treatments Act of 2022
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Helping Experts Accelerate Rare Treatments Act of 2022
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Helping Experts Accelerate Rare Treatments Act of 2021
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HEART Act HR 1184
Helping Experts Accelerate Rare Treatments Act of 2021
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HR 1184 The Heart Act
Helping Experts Accelerate Rare Treatments Act of 2021
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR7567 The Access to Rare Indications Act HR1184 The HEART Act
Helping Experts Accelerate Rare Treatments Act of 2021
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
HR 1184 The Heart Act
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR7567 The Access to Rare Indications Act HEART Act.
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR7567 The Access to Rare Indications Act HR1184 The HEART Act
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR7567 The Access to Rare Indications Act HEART Act.
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR7567 The Access to Rare Indications Act
To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR7567 The Access to Rare Indications Act HEART Act.
A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
Reducing Barriers to Substance Use Treatment Act
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
H.R. 3925: Reducing Barriers to Substance Use Treatment Act, drug shortages
Helping Experts Accelerate Rare Treatments Act of 2020
Client: FCS FOUNDATION · Firm: CONNECT 4 STRATEGIES, LLC
The Heart Act (HR 7567)
Helping Experts Accelerate Rare Treatments Act of 2020
Client: THE HAYSTACK PROJECT · Firm: CONNECT 4 STRATEGIES, LLC
HR 7567 The Access to Rare Indications Act
Prescription Digital Therapeutics to Support Recovery Act
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
Legislative and regulatory issues pertaining to Orexo. Implementation of the SUPPORT Act. Access to Digital Therapeutics (S. 3532) Digital Therapeutics Support Recovery Act.
Prescription Digital Therapeutics to Support Recovery Act
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
Legislative and regulatory issues pertaining to Orexo. Implementation of Comprehensive Addiction and Recovery Act 2016 (P.L. 114-255), 21st Century Cures Act. (P.L. 114-255)Support for Patients and Communities Act (P.L. 115-271) and CARES Act (P.L. 116-255) Access to Digital Therapeutics (S. 3532) Digital Therapeutics Support Recovery Act.
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINSTALHEIMER'S · Firm: CONNECT 4 STRATEGIES, LLC
HR4957 / S2387 Change Act. Concentrating on High Value Alzheimers Needs to get to an End
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGINASTALZHEIMER'S NETWORK · Firm: CONNECT 4 STRATEGIES, LLC
HR 4957 / S 2387 " The Change Act" Concentrating on High Value Alzheimers Needs to Get to and End
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINSTALHEIMER'S · Firm: CONNECT 4 STRATEGIES, LLC
S2387 and HR4957 The CHANGE Act.
Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINSTALHEIMER'S · Firm: CONNECT 4 STRATEGIES, LLC
HR4957 / S2387 Change Act. Concentrating on High Value Alzheimers Needs to get to an End
SUPPORT for Patients and Communities Act
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
s2680 / HR 6 Opiod Crisis Response Act 2018 Medication assisted therapy - opioids
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINSTALHEIMER'S · Firm: CONNECT 4 STRATEGIES, LLC
S2387 and HR4957 The CHANGE Act.
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINSTALHEIMER'S · Firm: CONNECT 4 STRATEGIES, LLC
HR4957 / S2387 Change Act. Concentrating on High Value Alzheimers Needs to get to an End
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGAINSTALHEIMER'S · Firm: CONNECT 4 STRATEGIES, LLC
HR4957 / S2387 Change Act. Concentrating on High Value Alzheimers Needs to get to an End
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2018
Client: USAGINASTALZHEIMER'S NETWORK · Firm: CONNECT 4 STRATEGIES, LLC
HR 4957 / S 2387 " The Change Act" Concentrating on High Value Alzheimers Needs to Get to and End
s2680 / HR 6 Opiod Crisis Response Act 2018 Medication assisted therapy - opioids
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
s916 Access to Emergency Medications Act
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
s916 Access to Emergency Medications Act Medication assisted therapy - opioids
S670 and HR1562 OTC Hearing Aid
S670 and HR1562 OTC Hearing Aid
Over-the-Counter Hearing Aid Act of 2017
Client: STARKEY HEARING TECHNOLOGIES · Firm: CONNECT 4 STRATEGIES, LLC
Over the counter hearing aid act HR1652 & S670
Over-the-Counter Hearing Aid Act of 2017
Client: STARKEY HEARING TECHNOLOGIES · Firm: CONNECT 4 STRATEGIES, LLC
S670 and HR1562 OTC Hearing Aid
Over-the-Counter Hearing Aid Act of 2017
Client: STARKEY HEARING TECHNOLOGIES · Firm: CONNECT 4 STRATEGIES, LLC
S670 and HR1562 OTC Hearing Aid
Over-the-Counter Hearing Aid Act of 2017
Client: STARKEY HEARING TECHNOLOGIES · Firm: CONNECT 4 STRATEGIES, LLC
Over the counter hearing aid act HR1652 & S670
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
s916 Access to Emergency Medications Act
Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Client: OREXO US, INC. · Firm: CONNECT 4 STRATEGIES, LLC
s916 Access to Emergency Medications Act
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Advancing Hope Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: CONNECT 4 STRATEGIES, LLC
Rare pediatric review voucher. S 1878 and HR 1537
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Advancing Hope Act of 2015
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: CONNECT 4 STRATEGIES, LLC
Rare pediatric review voucher. S 1878 and HR 1537
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
HR2536 & S1455 DATA 2000 Patient Caps.
HR2536 & S1455 DATA 2000 Patient Caps.
HR2536 & S1455 DATA 2000 Patient Caps.
HR2536 & S1455 DATA 2000 Patient Caps.
HR2536 & S1455 DATA 2000 Patient Caps.
HR2536 & S1455 DATA 2000 Patient Caps.
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: CONNECT 4 STRATEGIES, LLC
Rare pediatric review voucher. S 1878 and HR 1537
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Advancing Hope Act of 2016
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Advancing Hope Act of 2016
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: CONNECT 4 STRATEGIES, LLC
Rare pediatric review voucher. S 1878 and HR 1537
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare Pediatric Review Voucher
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare Pediatric Review Voucher
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Advancing Hope Act of 2015
Client: MAST THERAPEUTICS, INC. · Firm: CONNECT 4 STRATEGIES, LLC
HR 1537 Rare pediatric priority review voucher
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
Pediatric Priority review vouchers. HR1573 and S1878.
Higher Education and Employment Transparency Act
Client: THERABRON THERAPEUTICS, INC · Firm: CONNECT 4 STRATEGIES, LLC
HR1573 & S1878 Pediatric Pediatric Priority Review Voucher
HR2536 & S1455 DATA 2000 Patient Caps.
HR2536 & S1455 DATA 2000 Patient Caps.
General issue awareness related to ultra-rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2026 · first_quarter · Q1
General issue awareness related to ultra-rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2025 · fourth_quarter · Q4
General issue awareness related to ultra-rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2025 · third_quarter · Q3
General issue awareness related to ultra-rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2025 · second_quarter · Q2
General issue awareness related to ultra-rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2025 · first_quarter · Q1
General issue awareness related to ultra-rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2024 · fourth_quarter · Q4
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2024 · third_quarter · Q3
Legislative and regulatory issues related to Orexo.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2024 · third_quarter · Q3
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2024 · second_quarter · Q2
Legislative and regulatory issues related to Orexo.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2024 · second_quarter · Q2
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2024 · first_quarter · Q1
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2024 · first_quarter · Q1
Legislative and regulatory issues related to Orexo.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2023 · fourth_quarter · Q4
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2023 · fourth_quarter · Q4
Legislative and regulatory issues related to Orexo
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2023 · third_quarter · Q3
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2023 · third_quarter · Q3
Legislative and regulatory issues related to Orexo
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2023 · second_quarter · Q2
Legislative and regulatory issues related to Orexo
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2023 · second_quarter · Q2
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2023 · first_quarter · Q1
Ultra-rare disease health care issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2023 · first_quarter · Q1
Legislative and regulatory issues related to Orexo
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2022 · fourth_quarter · 4T
HEART Act HR 1184 and S 4071
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2022 · fourth_quarter · Q4
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2022 · fourth_quarter · Q4
Medicare, Medicaid and Healthcare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2022 · third_quarter · Q3
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2022 · third_quarter · Q3
HEART Act HR 1184 and S 4071
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2022 · third_quarter · Q3
Medicare, Medicaid and Healthcare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2022 · second_quarter · Q2
HEART Act HR 1184 and S 4071
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2022 · second_quarter · 2A
HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2022 · second_quarter · Q2
HEART Act HR1184 and S4071
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2022 · second_quarter · Q2
Legislative and regulatory issues pertaining to Orexo Access to treatment for SUD/OUD/MAT
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2022 · first_quarter · Q1
HEART Act HR 1184
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2022 · first_quarter · Q1
HR7567 The Access to Rare Indications Act HEART Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2022 · first_quarter · Q1
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2021 · fourth_quarter · Q4
HEART Act HR 1184
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2021 · fourth_quarter · Q4
HR7567 The Access to Rare Indications Act HEART Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2021 · fourth_quarter · Q4
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2021 · third_quarter · Q3
HR7567 The Access to Rare Indications Act HEART Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2021 · third_quarter · Q3
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2021 · second_quarter · Q2
HR 1184 The Heart Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2021 · second_quarter · Q2
HR7567 The Access to Rare Indications Act HEART Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2021 · second_quarter · Q2
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2021 · first_quarter · 1A
HR7567 The Access to Rare Indications Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2021 · first_quarter · Q1
HR 1184 The Heart Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2021 · first_quarter · Q1
HR7567 The Access to Rare Indications Act HR1184 The HEART Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2021 · first_quarter · Q1
Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2020 · fourth_quarter · Q4
Legislative and regulatory issues pertaining to Orexo. Implementation of the SUPPORT Act. Access to Digital Therapeutics (S. 3532) Digital Therapeutics Support Recovery Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2020 · fourth_quarter · Q4
HR 7567 The Access to Rare Indications Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2020 · fourth_quarter · Q4
The Heart Act (HR 7567)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2020 · third_quarter · Q3
Legislative and regulatory issues pertaining to Orexo. Implementation of Comprehensive Addiction and Recovery Act 2016 (P.L. 114-255), 21st Century Cures Act. (P.L. 114-255)Support for Patients and Communities Act (P.L. 115-271) and CARES Act (P.L. 116-255) Access to Digital Therapeutics (S. 3532) Digital Therapeutics Support Recovery Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2020 · third_quarter · Q3
FDA processes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2020 · second_quarter · Q2
Patient Access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2020 · second_quarter · Q2
FDA processes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AKCEA THERAPEUTICS, INC. via CONNECT 4 STRATEGIES, LLC
2020 · second_quarter · Q2
General pharmaceutical issues awareness
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2020 · second_quarter · Q2
General issue awareness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AKCEA THERAPEUTICS, INC. via CONNECT 4 STRATEGIES, LLC
2020 · first_quarter · Q1
General pharmaceutical issues awareness
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2020 · first_quarter · Q1
H.R. 3925: Reducing Barriers to Substance Use Treatment Act, drug shortages
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALPHA-1 FOUNDATION via CONNECT 4 STRATEGIES, LLC
2020 · second_quarter · RR
Medicare part B and D
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2020 · first_quarter · Q1
FDA processes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · Q4
CMS Coding process
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AKCEA THERAPEUTICS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · Q4
FDA drug process issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · Q4
CMS Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGAINSTALHEIMER'S via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · 4T
The Change Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGINASTALZHEIMER'S NETWORK via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · 4T
The Change Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · Q4
FTC policy and drug shortages
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · Q4
FDA processes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FCS FOUNDATION via CONNECT 4 STRATEGIES, LLC
2019 · fourth_quarter · RR
General Education and awareness
FERRING PHARMACEUTICALS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · third_quarter · Q3
Medicare issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AKCEA THERAPEUTICS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · third_quarter · Q3
FDA drug approval issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2019 · third_quarter · Q3
CMS Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGINASTALZHEIMER'S NETWORK via CONNECT 4 STRATEGIES, LLC
2019 · third_quarter · Q3
The Change Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2019 · third_quarter · Q3
Medicare and Medicaid access
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · second_quarter · Q2
Medicare issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2019 · second_quarter · 2A
CMS Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AKCEA THERAPEUTICS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · second_quarter · Q2
FDA drug approval issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2019 · second_quarter · Q2
CMS Issues
CMS Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGINASTALZHEIMER'S NETWORK via CONNECT 4 STRATEGIES, LLC
2019 · second_quarter · Q2
The Change Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2019 · second_quarter · Q2
Medicare and Medicaid access
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · second_quarter · RR
Medicare reimbursement
AKCEA THERAPEUTICS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · first_quarter · Q1
FDA drug approval issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AKCEA THERAPEUTICS, INC. via CONNECT 4 STRATEGIES, LLC
2019 · first_quarter · RR
Rare diseases
USAGINASTALZHEIMER'S NETWORK via CONNECT 4 STRATEGIES, LLC
2019 · first_quarter · Q1
The Change Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
USAGAINSTALHEIMER'S via CONNECT 4 STRATEGIES, LLC
2019 · first_quarter · Q1
General Issue Awareness and Education
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2019 · first_quarter · Q1
CMS Issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2018 · fourth_quarter · Q4
Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGAINSTALHEIMER'S via CONNECT 4 STRATEGIES, LLC
2018 · fourth_quarter · Q4
HR4957 / S2387 Change Act. Concentrating on High Value Alzheimers Needs to get to an End
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2018 · third_quarter · Q3
Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGINASTALZHEIMER'S NETWORK via CONNECT 4 STRATEGIES, LLC
2018 · third_quarter · Q3
HR 4957 / S 2387 " The Change Act" Concentrating on High Value Alzheimers Needs to Get to and End
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGAINSTALHEIMER'S via CONNECT 4 STRATEGIES, LLC
2018 · third_quarter · Q3
HR4957 / S2387 Change Act. Concentrating on High Value Alzheimers Needs to get to an End
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2018 · third_quarter · Q3
s2680 / HR 6 Opiod Crisis Response Act 2018 Medication assisted therapy - opioids
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2018 · first_quarter · 1A
Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2018 · second_quarter · Q2
Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGINASTALZHEIMER'S NETWORK via CONNECT 4 STRATEGIES, LLC
2018 · second_quarter · Q2
General disease awareness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
USAGAINSTALHEIMER'S via CONNECT 4 STRATEGIES, LLC
2018 · second_quarter · Q2
General disease awareness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2018 · second_quarter · Q2
s916 Access to Emergency Medications Act Medication assisted therapy - opioids
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2018 · second_quarter · Q2
340B Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE HAYSTACK PROJECT via CONNECT 4 STRATEGIES, LLC
2018 · first_quarter · Q1
340B Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OREXO US, INC. via CONNECT 4 STRATEGIES, LLC
2018 · first_quarter · Q1
s916 Access to Emergency Medications Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RECORDATI RARE DISEASES via CONNECT 4 STRATEGIES, LLC
2018 · first_quarter · Q1
Reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE